Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes (CADEN)

This study has been completed.
Texas Children's Hospital
The Methodist Hospital System
Center for Cell and Gene Therapy, Baylor College of Medicine
M.D. Anderson Cancer Center
Information provided by (Responsible Party):
Chrystal Louis, Baylor College of Medicine Identifier:
First received: August 4, 2009
Last updated: August 3, 2016
Last verified: August 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: July 2015
  Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: August 26, 2015